AppYea (APYP) 10-Q 20 May 24 2024 Q1 Quarterly report Financial data

Cover

Cover - shares	3 Months Ended
	Mar. 31, 2024	May 20, 2024
Cover [Abstract]
Document Type	10-Q
Amendment Flag	false
Document Quarterly Report	true
Document Transition Report	false
Document Period End Date	Mar. 31, 2024
Document Fiscal Period Focus	Q1
Document Fiscal Year Focus	2024
Current Fiscal Year End Date	--12-31
Entity File Number	000-55403
Entity Registrant Name	APPYEA, Inc.
Entity Central Index Key	0001568969
Entity Tax Identification Number	46-1496846
Entity Incorporation, State or Country Code	NV
Entity Address, Address Line One	16 Natan Alterman St
Entity Address, City or Town	Gan Yavne
Entity Address, Country	IL
City Area Code	(800)
Local Phone Number	674-3561
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	false
Entity Shell Company	false
Entity Common Stock, Shares Outstanding		451,113,064

Condensed Consolidated Balance

Condensed Consolidated Balance Sheets - USD ($) $ in Thousands	Mar. 31, 2024	Dec. 31, 2023
Current assets
Cash and cash equivalents	$ 373	$ 222
Accounts receivables	1
Other accounts receivables	30	42
Inventory	14	14
Total current assets	418	278
Non-current assets
Property and equipment, net	2	3
Intangible assets, net	238	193
Total non-current asset	240	196
Total assets	658	474
Current liabilities
Trade payables	24	51
Other accounts payable	679	694
Convertible loans at amortized cost	811	796
Convertible loans – At fair value	2,160	1,203
Financial liability at fair value	72	204
Total current liabilities	3,825	3,027
Total liabilities	3,825	3,027
AppYea Inc. Stockholders’ Deficiency:
Convertible preferred stock, $0.0001 par value
Common stock, $0.0001 par value	41	31
Stock payables	657	559
Additional Paid in Capital	3,719	3,197
Accumulated deficit	(7,570)	(6,326)
Total AppYea Inc. stockholders’ deficiency	(3,153)	(2,539)
Non-controlling interests	(14)	(14)
Total Deficiency	(3,167)	(2,553)
Total liabilities and deficiency	658	474
Related Party [Member]
Current liabilities
Short-term loans from related party	$ 79	$ 79

Condensed Consolidated Balanc_2

Condensed Consolidated Balance Sheets (Parenthetical) - $ / shares	Mar. 31, 2024	Dec. 31, 2023
Statement of Financial Position [Abstract]
Convertible preferred stock, par value	$ 0.0001	$ 0.0001
Common stock, par value	$ 0.0001	$ 0.0001

Condensed Consolidated Statemen

Condensed Consolidated Statements of Operations (Unaudited) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Income Statement [Abstract]
Sales	$ 13
Cost of sales	(3)
Gross profit	10
Research and development expenses	(60)	(9)
Sales and marketing	(54)
General and administrative expenses	(294)	(427)
Operating loss	(398)	(436)
Change in fair value of convertible loans and warrant liability	(824)	166
Financial income (expenses), net	(22)	(19)
Loss before income tax benefit	(1,244)	(289)
Income tax benefit
Net loss	(1,244)	(289)
Net loss attributable to AppYea Inc.	$ (1,244)	$ (289)
Net Loss per Common Share:
Net Loss Per Common Share: Basic	$ (0.003)	$ (0.001)
Net Loss Per Common Share: Diluted	$ (0.003)	$ (0.001)
Weighted Average number of Common Shares Outstanding basic	380,266,957	225,248,108
Weighted Average number of Common Shares Outstanding diluted	380,266,957	225,248,108

Condensed Consolidated Statem_2

Condensed Consolidated Statements of Changes in Deficiency (Unaudited) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Balance	$ (2,553)	$ (2,563)
Share based Compensation	147	279
Net loss	(1,244)	(289)
Shares to be issued		1
Shares to be issued to service providers	25
Issuance of Shares	383
Shares to be issued to investors	75
Options exercise
Share issuance upon conversion of Convertible notes.		161
Balance	(3,167)	$ (2,411)
Preferred Stock [Member]
Balance
Balance, shares	258,745	300,000
Share based Compensation
Net loss
Shares to be issued
Share issuance upon conversion of Convertible notes.
Share issuance upon conversion of Convertible notes, shares	(28,147)
Balance
Balance, shares	230,598	300,000
Common Stock [Member]
Balance	$ 31	$ 21
Balance, shares	328,836,657	220,930,798
Share based Compensation
Net loss
Shares to be issued
Shares to be issued to service providers
Issuance of Shares	$ 6
Issuance of Shares, shares	60,143,100
Shares to be issued to investors
Options exercise
Options exercise, shares	500,000
Share issuance upon conversion of Convertible notes.	$ 4	$ 1
Share issuance upon conversion of Convertible notes, shares	42,217,500	8,634,616
Balance	$ 41	$ 22
Balance, shares	431,697,257	229,565,414
Additional Paid-in Capital [Member]
Balance	$ 3,197	$ 1,912
Share based Compensation	147	279
Net loss
Shares to be issued
Shares to be issued to service providers
Issuance of Shares	379
Shares to be issued to investors
Options exercise
Share issuance upon conversion of Convertible notes.	(4)	160
Balance	3,719	2,351
Stock Payables [Member]
Balance	559	27
Share based Compensation
Net loss
Shares to be issued		1
Shares to be issued to service providers	25
Issuance of Shares	(2)
Shares to be issued to investors	75
Options exercise
Share issuance upon conversion of Convertible notes.
Balance	657	28
Retained Earnings [Member]
Balance	(6,326)	(4,509)
Share based Compensation
Net loss	(1,244)	(289)
Shares to be issued
Shares to be issued to service providers
Issuance of Shares
Shares to be issued to investors
Options exercise
Share issuance upon conversion of Convertible notes.
Balance	(7,570)	(4,798)
Parent [Member]
Balance	(2,539)	(2,549)
Share based Compensation	147	279
Net loss	(1,244)	(289)
Shares to be issued		1
Shares to be issued to service providers	25
Issuance of Shares	383
Shares to be issued to investors	75
Options exercise
Share issuance upon conversion of Convertible notes.		161
Balance	(3,153)	(2,397)
Noncontrolling Interest [Member]
Balance	(14)	(14)
Share based Compensation
Net loss
Shares to be issued
Shares to be issued to service providers
Issuance of Shares
Shares to be issued to investors
Options exercise
Share issuance upon conversion of Convertible notes.
Balance	$ (14)	$ (14)

Condensed Consolidated Statem_3

Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Cash flows from operating activities:
Net loss	$ (1,244)	$ (289)
Adjustments to reconcile loss to net cash used in operating activities:
Depreciation and amortization	6	6
Share based compensation	172	279
Change in fair value of convertible loans and warrant liability	824	(147)
Financial expenses, net	14
Changes in operating assets and liabilities:
Other current assets	11	1
Accounts payables	(24)	74
Accounts payables – related party	(16)	(21)
Net cash used in operating activities	(257)	(97)
Cash flows from investing activities:
Research and development expenses capitalization	(50)
Net cash used in investing activities	(50)
Cash flows from financing activities:
Proceeds from issuance of Common Stock	381
Proceeds from convertible Note received, net of issuance expenses		141
Proceeds on account of Shares to be issued	75
Net cash provided by financing activities	456	141
Foreign exchange on Cash and cash equivalents	3	(4)
Change in cash and cash equivalents	152	40
Cash and cash equivalents at beginning of period	222	60
Cash and cash equivalents at end of period	$ 373	$ 100

Pay vs Performance Disclosure

Pay vs Performance Disclosure - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Pay vs Performance Disclosure [Table]
Net Income (Loss)	$ (1,244)	$ (289)

Insider Trading Arrangements

Insider Trading Arrangements	3 Months Ended
	Mar. 31, 2024
Insider Trading Arrangements [Line Items]
Rule 10b5-1 Arrangement Adopted	false
Non-Rule 10b5-1 Arrangement Adopted	false
Rule 10b5-1 Arrangement Terminated	false
Non-Rule 10b5-1 Arrangement Terminated	false

GENERAL

GENERAL	3 Months Ended
	Mar. 31, 2024
Organization, Consolidation and Presentation of Financial Statements [Abstract]
GENERAL	NOTE 1 - GENERAL AppYea, Inc. (“AppYea”, “the Company”, “we” or “us”) was incorporated in the State of South Dakota on November 26, 2012 to engage in the acquisition, purchase, maintenance and creation of mobile software applications. The Company is in the development stage with no significant revenues and no operating history. On November 1, 2021 the Company was redomiciled in the State of Nevada. The Company’s common stock is traded on the OTC Markets, OTCQB tier, under the symbol “APYP”. SleepX LTD is a company formed under the laws of the State of Israel and a wholly owned subsidiary of the Company (“SleepX”). SleepX is a research and development company that has developed a proprietary product for monitoring and treating sleep apnea and snoring. The technology is protected by several international patents and the Company started serial production in 2023. Subject to raising working capital, of which no assurance can be provided, the Company intends to focus on further development and commercialization of its products. SleepX has incorporated, together with an unrelated third party, a privately held company under the laws of the State of Israel named Ta-nooma Ltd. (“Ta-nooma”). Ta-nooma has developed sleeping monitoring technology for which patent applications were filed and has no revenue from operations. Since its incorporation and as of the financial statements date, Sleepx holds 66.7% of the voting interest of Ta-nooma. Strategic Development The company flagship product is AppySleep – A Biofeedback snoring treatment wristband, combined with the AppySleep App (“AppySleep”). The AppySleep product is currently in serial manufacturing and commercial stage. Financial position The financial statements are presented on a going-concern basis. To date, the Company has not generated any significant revenues, suffered recurring losses from operations, incurred negative cash flows from operating activities, and is dependent upon external sources for financing its operations. As of March 31, 2024, the Company had an accumulated deficit of $ 7,570,000 3,153,000 The financial statements do not include any adjustments for the values of assets and liabilities and their classification that may be necessary in the event that the Company is no longer able to continue its operations as a “going concern”. APPYEA INC. NOTES TO THE FINANCIAL STATEMENTS

SIGNIFICANT ACCOUNTING POLICIES

SIGNIFICANT ACCOUNTING POLICIES	3 Months Ended
	Mar. 31, 2024
Accounting Policies [Abstract]
SIGNIFICANT ACCOUNTING POLICIES	NOTE 2 - SIGNIFICANT ACCOUNTING POLICIES The interim financial statements have been prepared in accordance with generally accepted accounting principles in the United States of America (“U.S. GAAP”). The interim financial statements do not include a full disclosure as required in annual financial statements and should be read with the annual financial statements of the Company as of December 31, 2023 from which the accompanying condensed consolidated balance sheet dated December 31, 2023, was derived. The accounting policies implemented in the interim financial statements are consistent with the accounting policies implemented in the annual financial statements as of December 31, 2023, except of the following accounting pronouncement adopted by the Company. Recently Issued Accounting Pronouncements Effective January 1, 2024, the Company adopted ASU 2020-06, “Debt – Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging – Contracts in Entity’s Own Equity (Subtopic 815-40)” (“ASU 2020-06”), which is intended to address issues identified as a result of the complexity associated with applying GAAP for certain financial instruments with characteristics of liabilities and equity. For convertible instruments, ASU 2020-06 reduces the number of accounting models for convertible debt instruments and convertible preferred stocks, and enhances information transparency by making targeted improvements to the disclosures for convertible instruments and earnings-per-share guidance on the basis of feedback from financial statement users. The adoption of this new accounting guidance did not have an effect on the consolidated financial statements. Effective January 1, 2023, the Company adopted ASU 2016-13, “Financial Instruments-Credit Losses (Topic 326),” referred to herein as ASU 2016-13, which significantly changes how entities will account for credit losses for most financial assets and certain other instruments that are not measured at fair value through net income. ASU 2016-13 replaced the existing incurred loss model with an expected credit loss model that requires entities to estimate an expected lifetime credit loss on most financial assets and certain other instruments. Under ASU 2016-13 credit impairment is recognized as an allowance for credit losses, rather than as a direct write-down of the amortized cost basis of a financial asset. The impairment allowance is a valuation account deducted from the amortized cost basis of financial assets to present the net amount expected to be collected on the financial asset. Once the new pronouncement is adopted by the Company, the allowance for credit losses must be adjusted for management’s current estimate at each reporting date. The new guidance provides no threshold for recognition of impairment allowance. Therefore, entities must also measure expected credit losses on assets that have a low risk of loss. For instance, trade receivables that are either current or not yet due may not require an allowance reserve under current generally accepted accounting principles, but under the new standard, the Company will have to estimate an allowance for expected credit losses on trade receivables under ASU 2016-13. The Company determined the adoption of this new accounting guidance and the effect on its financial statements throughout the period until implementation, and have no impact on the financial statements. In December 2023, the FASB issued ASU 2023-09 “Income Taxes (Topic 740): Improvements to Income Tax Disclosures” related to improvements to income tax disclosures. The amendments in this update require enhanced jurisdictional and other disaggregated disclosures for the effective tax rate reconciliation and income taxes paid. The amendments in this update are effective for fiscal years beginning after December 15, 2024. The adoption of this pronouncement is not expected to have a material impact on the Company’s financial statements. Use of Estimates in Preparation of Financial Statements The preparation of consolidated financial statements in conformity with U.S. GAAP accounting principles requires management to make estimates and assumptions. The Company’s management believes that the estimates, judgments, and assumptions used are reasonable based upon information available at the time they are made. These estimates, judgments and assumptions can affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the dates of the financial statements, and the reported amounts of expenses during the reporting period. Actual results could differ from those estimates. Revenue Recognition The Company recognizes revenue under ASC 606, Revenue Recognition We determine revenue recognition through the following steps: (1) identification of the contract with a customer; (2) identification of the performance obligations in the contract; (3) determination of the transaction price; (4) allocation of the transaction price to the performance obligations in the contract; and (5) recognition of revenue when, or as, a performance obligation is satisfied. Our contracts are typically governed by a customer purchase order. The contract generally specifies the delivery of what constitutes a single performance obligation. If an arrangement involves multiple performance obligations, the items are analyzed to determine the separate units of accounting, whether the items have value on a standalone basis and whether there is objective and reliable evidence of their standalone selling price. The total contract transaction price is allocated to the identified performance obligations based upon the relative standalone selling prices of the performance obligations. The standalone selling price is based on an observable price for services sold to other comparable customers. As discussed in more detail below, revenue is recognized when a customer obtains control of promised goods or services under the terms of a contract and is measured as the amount of consideration we expect to receive in exchange for transferring goods or providing services. We do not have any material extended payment terms, as payment is due at or shortly after the time of the sale. Sales, value-added and other taxes collected concurrently with revenue producing activities are excluded from revenue. A contract liability is recognized as deferred revenue when we invoice customers, or receive customer cash payments, in advance of satisfying the related performance obligation(s) under the terms of a contract. Deferred revenue is recognized as revenue when we have satisfied the related performance obligation. We have one main revenue stream: wristband sales, with the AppySleep App. For this revenue stream, our performance obligations are satisfied at a point in time, and therefore, revenue is recognized at point in time when a customer takes control of the good or asset created by the service. Factors that may indicate transfer of control are when we have the right to receive payment for the good or service, when the legal title of the asset has been transferred, physical possession of the asset has been transferred, the customer obtains the significant risks and rewards of ownership of the asset, and the customer accepts the asset. For customers, control is transferred upon delivery. We leverage drop-ship shipments with our partners and suppliers to deliver wristbands to our customers without having to physically hold the inventory at our warehouses, thereby increasing efficiency and reducing costs. We recognize revenue for drop-ship arrangements on a gross basis as the principal in the transaction when the product is received by the customer because we control the product prior to transfer to the customer. We also assume primary responsibility for the fulfillment in the arrangement, we assume inventory risk if something were to happen to the hardware during shipping, we set the price of the product charged to the customer. The Company intend to recognize records reductions to Products net sales related to future product returns, price protection and other customer incentive programs based on the Company’s expectations and historical experience. APPYEA INC. NOTES TO THE FINANCIAL STATEMENTS

RELATED PARTY BALANCES AND TRAN

RELATED PARTY BALANCES AND TRANSACTIONS	3 Months Ended
	Mar. 31, 2024
Related Party Transactions [Abstract]
RELATED PARTY BALANCES AND TRANSACTIONS	NOTE 3 - RELATED PARTY BALANCES AND TRANSACTIONS A. Short-term loans from related parties During 2021, SleepX borrowed from Nexense Technologies USA. Inc., a Delaware corporation which is majority owned by Boris Molchadsky, the Company’s Chairman. an aggregate amount of $ 47,623 5.18 During 2020, the minority shareholder of Ta-nooma advanced a loan to Ta-nooma in the amount of NIS 115,725 115,725 31,906 B. Balances with related parties SCHEDULE OF BALANCE WITH RELATED PARTIES March 31, 2024 December 31, 2023 In U.S. dollars in thousands Liabilities: Employees and payroll accruals 267 498 Related party payables 208 129 Short term loans 79 79 C. Transactions with related parties SCHEDULE OF TRANSACTION WITH RELATED PARTIES 2024 2023 For the three months ended March 31, 2024 2023 In U.S. dollars in thousands Expenses: Salaries and related cost (including stock-based compensation in the amount of $ 116,000 721,000 190 1,067 Both the Chairman and the chief financial officer are directors in the Company and do not receive compensation for their directorship roles. Company’s Bylaws provide that a director or officer shall be indemnified and held harmless by the Corporation, to the fullest extent permitted by the laws of the State of Nevada. APPYEA INC. NOTES TO THE FINANCIAL STATEMENTS

CONVERTIBLE LOANS AND WARRANTS

CONVERTIBLE LOANS AND WARRANTS	3 Months Ended
	Mar. 31, 2024
Convertible Loans And Warrants
CONVERTIBLE LOANS AND WARRANTS	NOTE 4 - CONVERTIBLE LOANS AND WARRANTS The following table summarizes fair value measurements by level as of March 31, 2024 and December 31, 2023 measured at fair value on a recurring basis: SCHEDULE OF FAIR VALUE RECURRING BASIS December 31, 2023 Level 1 Level 2 Level 3 Total In U.S. dollars Assets None - - - - Liabilities Convertible Loans - - 1,203 1,203 Financial liability - 204 204 March 31, 2024 Level 1 Level 2 Level 3 Total In U.S. dollars Assets None - - - - Liabilities Convertible Loans - - 2,160 2,160 Financial liability - 72 72 APPYEA INC. NOTES TO THE FINANCIAL STATEMENTS NOTE 4 - CONVERTIBLE LOANS AND WARRANTS (cont.) The Convertible Loans changes consist of the following as of March 31, 2024 and December 31, 2023: SCHEDULE OF CONVERTIBLE LOANS AT FAIR VALUE March 31, 2024 December 31, 2023 Convertible Loans at Fair Value March 31, 2024 December 31, 2023 $000 Opening Balance, (including short term loans from related party which is also convertible) 1,203 2,257 Additional convertible loans (a) - 153 Conversion of convertible loan (b) - (243 ) Decrease of notes purchased - (530 ) Change in fair value of convertible loans liability 957 (434 ) Closing balance 2,160 1,203 (a) During the quarter ended March 31, 2024, and the year ended December 31, 2023, the Company raised a principal amount of nill 152,750 (b) During the quarter ended March 31, 2024, and the year ended December 31, 2023 a total amount of nill 242,538 8,634,616 The estimated fair values of the Convertible loans were measured according to the Monte Carlo Model using the following assumptions: SCHEDULE OF FAIR VALUES OF WARRANTS AND CONVERTIBLE LOAN ASSUMPTION USED As of As of March 31, 2024 December 31, 2023 Expected term (in years) 0.25 0.5 Expected average (Monte Carlo) volatility 83 % 213 % Expected dividend yield - - Risk-free interest rate 5.46 % 5.26 % WACC 27 % 27 % APPYEA INC. NOTES TO THE FINANCIAL STATEMENTS NOTE 4 - CONVERTIBLE LOANS AND WARRANTS (cont.) The following table summarizes information relating to outstanding and exercisable warrants as of December 31, 2023: SUMMARIZES RELATING TO OUTSTANDING AND EXERCISABLE WARRANTS Warrants Outstanding and Exercisable Number of Warrants Weighted Average Remaining Contractual life (in years) Weighted Average Exercise Price Valuation as of December 31, 2023 8,334 2.16 0.6 $ 23 32,500 2.61 0.6 $ 116 7,000,000 0.46 0.015 $ 203,718 The following table summarizes information relating to outstanding warrants as of March 31, 2024: Warrants Outstanding Number of Warrants Weighted Average Remaining Contractual life (in years) Weighted Average Exercise Price Valuation as of March 31, 2024 7,000,000 0.21 0.01024 $ 71,702 8,334 1.91 0.6 $ 23 32,500 2.36 0.6 $ 116 The estimated fair values of the Warrants were measured according to the data as follows: SCHEDULE OF FAIR VALUES OF WARRANTS AND CONVERTIBLE LOAN ASSUMPTION USED As of As of March 31, 2024 December 31, 2023 Expected term 0.21 0.46 Expected average volatility 87 % 224 % Expected dividend yield - - Risk-free interest rate 4.19 % 5.3 % Common Stock Market Value $ 0.01024 $ 0.015 Warrants rights outstanding measurement input $ 0.01024 $ 0.015 APPYEA INC. NOTES TO THE FINANCIAL STATEMENTS NOTE 4 - CONVERTIBLE LOANS AND WARRANTS (cont.) The Convertible Loans at amortized cost changes consist of the following as of March 31, 2024 and December 31, 2023: SCHEDULE OF CONVERTIBLE LOANS AMORTIZED COST March 31, 2024 December 31, 2023 $000 Opening balance 796 - Transition from convertible loans measured at fair value to measurement at amortized cost - 530 Beneficial conversion feature - (66 ) Financial expenses related to transition from fair value measurement to amortized cost - 304 Accrued interest through profit or loss 15 28 Closing balance 811 796

STOCK BASED COMPENSATION

STOCK BASED COMPENSATION	3 Months Ended
	Mar. 31, 2024
Retirement Benefits [Abstract]
STOCK BASED COMPENSATION	NOTE 5 - STOCK BASED COMPENSATION A. The table below depicts the number of options granted to employees and service providers: SCHEDULE OF NUMBER OF OPTIONS Three months ended March 31, 2024 Number of Weighted average exercise price options in USD Options outstanding at January 1, 2024 62,349,647 $ 0.0007 Options granted during the period 7,900,000 $ 0.00373 Options exercised during the period* (500,000 ) $ 0.0001 Options outstanding at the end of period 69,749,647 $ 0.00107 Options exercisable at the end of period 25,650,311 $ 0.00136 * A board member exercised his options into shares during the quarter For the three months ended March 31, 2024 and 2023 the company recognized expenses, to such options, in the amount of $ 147,000 279,000 APPYEA INC. NOTES TO THE FINANCIAL STATEMENTS

SIGNIFICANT EVENTS DURING THE P

SIGNIFICANT EVENTS DURING THE PERIOD	3 Months Ended
	Mar. 31, 2024
Significant Events During Period
SIGNIFICANT EVENTS DURING THE PERIOD	NOTE 6 - SIGNIFICANT EVENTS DURING THE PERIOD A. On January 1, 2024, the Company engaged with a consultant. For his services he was granted stock option to purchase 2,300,000 34,350 The Options are vested on a monthly basis, over a period of 30 months as of the commencement date ending June 30, 2026. The options are exercisable at a per share exercise price of $ 0.01 B. On January 1, 2024, the Company engaged with an additional consultant. For his services, he was granted a stock option to purchase 600,000 8,961 The Options are vested on a monthly basis, over a period of 30 months as of the Commencement Date ending June 30, 2026. The Option are exercisable at a per share exercise price of $ 0.01 C. On January 1, 2024, the Company engaged with a note holder as a consultant. For his services, he was granted a stock option to purchase 5,000,000 of the Company’s Common Stock, valued at $ 74,675 . Upon grant, the Options vest on a monthly basis, over a period of 12 months as of the Commencement Date ending December 31, 2024. The Option are exercisable at a per share exercise price of $ 0.0001 D. During the first quarter of 2024, the company received an additional investment of $ 456,431 7,500,000 E. On August 11, 2022, a lawsuit was filed in the Tel Aviv Magistrate’s Court against our Chairman and majority shareholder, Boris Molchadsky, G.P.I.S Ltd., an entity controlled by Mr. Molchadsky, Nexsense, Inc. (the former shareholder of SleepX Ltd.) and SleepX, Ltd., our subsidiary (collectively, the “Defendants”) [Civil lawsuit number 25441-08-22]. The suit was filed by a fund operating out of Israel. A copy of the claim was served to the defendants only six months after it was submitted to court, on February 21, 2023. The lawsuit is based on the alleged breach of partnership and loan agreements as well as other related allegations, including violation of agreements reached in a mediation proceeding that took place in 2015. On July 24, 2023, the Defendants (except for Nexsense, Inc.) filed a statement of defense, denying the allegations and argued that the claim should be dismissed, due to the statute of limitations, lack of cause of action, lack of jurisdiction, delay in filing the claim, and respecting SleepX, also due to the lack of legal rivalry between SleepX and the plaintiff. Recently, the Magistrate’s Court in Tel Aviv accepted the request regarding lack of material jurisdiction, and the claim was then transferred to the economic department of the District Court in Tel Aviv. A preliminary hearing was held on February 14, 2024. The presiding judge did not rule on the preliminary pleadings and urged the parties to attempt mediation before the ruling. The parties are considering different mediators (which must be mutually agreed to) and following the selection of a mediator, the parties will schedule a date for the mediation. The Company cannot, at this stage, know the effects, if any, of these actions on its subsidiary SleepX and / or the Company, and accordingly, no provision was recorded.

SUBSEQUENT EVENTS

SUBSEQUENT EVENTS	3 Months Ended
	Mar. 31, 2024
Subsequent Events [Abstract]
SUBSEQUENT EVENTS	NOTE 7 - SUBSEQUENT EVENTS A. On May 13, 2024, Mr. Neil Kline announced the company on his resignation from the board of directors of the company. In Parallel, Mr. Kline signed an advisor agreement with the company to serve as an advisor of the Board, and provide services related to the development of company future products, creating marketing tools for company needs, and assist with filings and projects of the company. B. On May 14, 2024, the Board of the Company (the “Boad”) approved the conversion of outstanding amounts owed to its officers and directors for unpaid compensation for options of the Company’s common stock, as follows: Boris Molchadsky, the Company chairman, and Asaf Porat, the Company CFO, agreed to convert a portion their unpaid compensation into options for shares of the Company’s common stock at a per share conversion rate of $ 0.07 0.04 0.04 70,000 50,000 th earlier 1.5 6,959,692 C. In addition, the Board approved the issuance of stock option to purchase 6,000,000 0.0001 following the issuance by the Company of at least 100 49,492 197,966

SIGNIFICANT ACCOUNTING POLICI_2

SIGNIFICANT ACCOUNTING POLICIES (Policies)	3 Months Ended
	Mar. 31, 2024
Accounting Policies [Abstract]
Recently Issued Accounting Pronouncements	Recently Issued Accounting Pronouncements Effective January 1, 2024, the Company adopted ASU 2020-06, “Debt – Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging – Contracts in Entity’s Own Equity (Subtopic 815-40)” (“ASU 2020-06”), which is intended to address issues identified as a result of the complexity associated with applying GAAP for certain financial instruments with characteristics of liabilities and equity. For convertible instruments, ASU 2020-06 reduces the number of accounting models for convertible debt instruments and convertible preferred stocks, and enhances information transparency by making targeted improvements to the disclosures for convertible instruments and earnings-per-share guidance on the basis of feedback from financial statement users. The adoption of this new accounting guidance did not have an effect on the consolidated financial statements. Effective January 1, 2023, the Company adopted ASU 2016-13, “Financial Instruments-Credit Losses (Topic 326),” referred to herein as ASU 2016-13, which significantly changes how entities will account for credit losses for most financial assets and certain other instruments that are not measured at fair value through net income. ASU 2016-13 replaced the existing incurred loss model with an expected credit loss model that requires entities to estimate an expected lifetime credit loss on most financial assets and certain other instruments. Under ASU 2016-13 credit impairment is recognized as an allowance for credit losses, rather than as a direct write-down of the amortized cost basis of a financial asset. The impairment allowance is a valuation account deducted from the amortized cost basis of financial assets to present the net amount expected to be collected on the financial asset. Once the new pronouncement is adopted by the Company, the allowance for credit losses must be adjusted for management’s current estimate at each reporting date. The new guidance provides no threshold for recognition of impairment allowance. Therefore, entities must also measure expected credit losses on assets that have a low risk of loss. For instance, trade receivables that are either current or not yet due may not require an allowance reserve under current generally accepted accounting principles, but under the new standard, the Company will have to estimate an allowance for expected credit losses on trade receivables under ASU 2016-13. The Company determined the adoption of this new accounting guidance and the effect on its financial statements throughout the period until implementation, and have no impact on the financial statements. In December 2023, the FASB issued ASU 2023-09 “Income Taxes (Topic 740): Improvements to Income Tax Disclosures” related to improvements to income tax disclosures. The amendments in this update require enhanced jurisdictional and other disaggregated disclosures for the effective tax rate reconciliation and income taxes paid. The amendments in this update are effective for fiscal years beginning after December 15, 2024. The adoption of this pronouncement is not expected to have a material impact on the Company’s financial statements.
Use of Estimates in Preparation of Financial Statements	Use of Estimates in Preparation of Financial Statements The preparation of consolidated financial statements in conformity with U.S. GAAP accounting principles requires management to make estimates and assumptions. The Company’s management believes that the estimates, judgments, and assumptions used are reasonable based upon information available at the time they are made. These estimates, judgments and assumptions can affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the dates of the financial statements, and the reported amounts of expenses during the reporting period. Actual results could differ from those estimates.
Revenue Recognition	Revenue Recognition The Company recognizes revenue under ASC 606, Revenue Recognition We determine revenue recognition through the following steps: (1) identification of the contract with a customer; (2) identification of the performance obligations in the contract; (3) determination of the transaction price; (4) allocation of the transaction price to the performance obligations in the contract; and (5) recognition of revenue when, or as, a performance obligation is satisfied. Our contracts are typically governed by a customer purchase order. The contract generally specifies the delivery of what constitutes a single performance obligation. If an arrangement involves multiple performance obligations, the items are analyzed to determine the separate units of accounting, whether the items have value on a standalone basis and whether there is objective and reliable evidence of their standalone selling price. The total contract transaction price is allocated to the identified performance obligations based upon the relative standalone selling prices of the performance obligations. The standalone selling price is based on an observable price for services sold to other comparable customers. As discussed in more detail below, revenue is recognized when a customer obtains control of promised goods or services under the terms of a contract and is measured as the amount of consideration we expect to receive in exchange for transferring goods or providing services. We do not have any material extended payment terms, as payment is due at or shortly after the time of the sale. Sales, value-added and other taxes collected concurrently with revenue producing activities are excluded from revenue. A contract liability is recognized as deferred revenue when we invoice customers, or receive customer cash payments, in advance of satisfying the related performance obligation(s) under the terms of a contract. Deferred revenue is recognized as revenue when we have satisfied the related performance obligation. We have one main revenue stream: wristband sales, with the AppySleep App. For this revenue stream, our performance obligations are satisfied at a point in time, and therefore, revenue is recognized at point in time when a customer takes control of the good or asset created by the service. Factors that may indicate transfer of control are when we have the right to receive payment for the good or service, when the legal title of the asset has been transferred, physical possession of the asset has been transferred, the customer obtains the significant risks and rewards of ownership of the asset, and the customer accepts the asset. For customers, control is transferred upon delivery. We leverage drop-ship shipments with our partners and suppliers to deliver wristbands to our customers without having to physically hold the inventory at our warehouses, thereby increasing efficiency and reducing costs. We recognize revenue for drop-ship arrangements on a gross basis as the principal in the transaction when the product is received by the customer because we control the product prior to transfer to the customer. We also assume primary responsibility for the fulfillment in the arrangement, we assume inventory risk if something were to happen to the hardware during shipping, we set the price of the product charged to the customer. The Company intend to recognize records reductions to Products net sales related to future product returns, price protection and other customer incentive programs based on the Company’s expectations and historical experience.

RELATED PARTY BALANCES AND TR_2

RELATED PARTY BALANCES AND TRANSACTIONS (Tables)	3 Months Ended
	Mar. 31, 2024
Related Party Transactions [Abstract]
SCHEDULE OF BALANCE WITH RELATED PARTIES	SCHEDULE OF BALANCE WITH RELATED PARTIES March 31, 2024 December 31, 2023 In U.S. dollars in thousands Liabilities: Employees and payroll accruals 267 498 Related party payables 208 129 Short term loans 79 79
SCHEDULE OF TRANSACTION WITH RELATED PARTIES	SCHEDULE OF TRANSACTION WITH RELATED PARTIES 2024 2023 For the three months ended March 31, 2024 2023 In U.S. dollars in thousands Expenses: Salaries and related cost (including stock-based compensation in the amount of $ 116,000 721,000 190 1,067

CONVERTIBLE LOANS AND WARRANTS

CONVERTIBLE LOANS AND WARRANTS (Tables)	3 Months Ended
	Mar. 31, 2024
Class of Warrant or Right [Line Items]
SCHEDULE OF FAIR VALUE RECURRING BASIS	SCHEDULE OF FAIR VALUE RECURRING BASIS December 31, 2023 Level 1 Level 2 Level 3 Total In U.S. dollars Assets None - - - - Liabilities Convertible Loans - - 1,203 1,203 Financial liability - 204 204 March 31, 2024 Level 1 Level 2 Level 3 Total In U.S. dollars Assets None - - - - Liabilities Convertible Loans - - 2,160 2,160 Financial liability - 72 72
SCHEDULE OF CONVERTIBLE LOANS AT FAIR VALUE	SCHEDULE OF CONVERTIBLE LOANS AT FAIR VALUE March 31, 2024 December 31, 2023 Convertible Loans at Fair Value March 31, 2024 December 31, 2023 $000 Opening Balance, (including short term loans from related party which is also convertible) 1,203 2,257 Additional convertible loans (a) - 153 Conversion of convertible loan (b) - (243 ) Decrease of notes purchased - (530 ) Change in fair value of convertible loans liability 957 (434 ) Closing balance 2,160 1,203 (a) During the quarter ended March 31, 2024, and the year ended December 31, 2023, the Company raised a principal amount of nill 152,750 (b) During the quarter ended March 31, 2024, and the year ended December 31, 2023 a total amount of nill 242,538 8,634,616
SCHEDULE OF FAIR VALUES OF WARRANTS AND CONVERTIBLE LOAN ASSUMPTION USED	The estimated fair values of the Warrants were measured according to the data as follows: SCHEDULE OF FAIR VALUES OF WARRANTS AND CONVERTIBLE LOAN ASSUMPTION USED As of As of March 31, 2024 December 31, 2023 Expected term 0.21 0.46 Expected average volatility 87 % 224 % Expected dividend yield - - Risk-free interest rate 4.19 % 5.3 % Common Stock Market Value $ 0.01024 $ 0.015 Warrants rights outstanding measurement input $ 0.01024 $ 0.015
SUMMARIZES RELATING TO OUTSTANDING AND EXERCISABLE WARRANTS	The following table summarizes information relating to outstanding and exercisable warrants as of December 31, 2023: SUMMARIZES RELATING TO OUTSTANDING AND EXERCISABLE WARRANTS Warrants Outstanding and Exercisable Number of Warrants Weighted Average Remaining Contractual life (in years) Weighted Average Exercise Price Valuation as of December 31, 2023 8,334 2.16 0.6 $ 23 32,500 2.61 0.6 $ 116 7,000,000 0.46 0.015 $ 203,718 The following table summarizes information relating to outstanding warrants as of March 31, 2024: Warrants Outstanding Number of Warrants Weighted Average Remaining Contractual life (in years) Weighted Average Exercise Price Valuation as of March 31, 2024 7,000,000 0.21 0.01024 $ 71,702 8,334 1.91 0.6 $ 23 32,500 2.36 0.6 $ 116
SCHEDULE OF CONVERTIBLE LOANS AMORTIZED COST	The Convertible Loans at amortized cost changes consist of the following as of March 31, 2024 and December 31, 2023: SCHEDULE OF CONVERTIBLE LOANS AMORTIZED COST March 31, 2024 December 31, 2023 $000 Opening balance 796 - Transition from convertible loans measured at fair value to measurement at amortized cost - 530 Beneficial conversion feature - (66 ) Financial expenses related to transition from fair value measurement to amortized cost - 304 Accrued interest through profit or loss 15 28 Closing balance 811 796
Old CLA [Member]
Class of Warrant or Right [Line Items]
SCHEDULE OF FAIR VALUES OF WARRANTS AND CONVERTIBLE LOAN ASSUMPTION USED	The estimated fair values of the Convertible loans were measured according to the Monte Carlo Model using the following assumptions: SCHEDULE OF FAIR VALUES OF WARRANTS AND CONVERTIBLE LOAN ASSUMPTION USED As of As of March 31, 2024 December 31, 2023 Expected term (in years) 0.25 0.5 Expected average (Monte Carlo) volatility 83 % 213 % Expected dividend yield - - Risk-free interest rate 5.46 % 5.26 % WACC 27 % 27 %

STOCK BASED COMPENSATION (Table

STOCK BASED COMPENSATION (Tables)	3 Months Ended
	Mar. 31, 2024
Consultants and Employees [Member]
SCHEDULE OF NUMBER OF OPTIONS	SCHEDULE OF NUMBER OF OPTIONS Three months ended March 31, 2024 Number of Weighted average exercise price options in USD Options outstanding at January 1, 2024 62,349,647 $ 0.0007 Options granted during the period 7,900,000 $ 0.00373 Options exercised during the period* (500,000 ) $ 0.0001 Options outstanding at the end of period 69,749,647 $ 0.00107 Options exercisable at the end of period 25,650,311 $ 0.00136 * A board member exercised his options into shares during the quarter

GENERAL (Details Narrative)

GENERAL (Details Narrative) - USD ($) $ in Thousands	Mar. 31, 2024	Dec. 31, 2023
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Accumulated deficit	$ (7,570)	$ (6,326)
Stockholders' deficiency	$ (3,153)	$ (2,539)

SCHEDULE OF BALANCE WITH RELATE

SCHEDULE OF BALANCE WITH RELATED PARTIES (Details) - USD ($) $ in Thousands	Mar. 31, 2024	Dec. 31, 2023
Liabilities:
Employees and payroll accruals	$ 267	$ 498
Related party payables	208	129
Short term loans	$ 79	$ 79

SCHEDULE OF TRANSACTION WITH RE

SCHEDULE OF TRANSACTION WITH RELATED PARTIES (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Related Party Transactions [Abstract]
Salaries and related cost (including stock-based compensation in the amount of $116,000 and $721,000, respectively)	$ 190	$ 1,067

SCHEDULE OF TRANSACTION WITH _2

SCHEDULE OF TRANSACTION WITH RELATED PARTIES (Details) (Parenthetical) - USD ($)	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Related Party Transactions [Abstract]
Shared based compensation	$ 116,000	$ 721,000

RELATED PARTY BALANCES AND TR_3

RELATED PARTY BALANCES AND TRANSACTIONS (Details Narrative)	3 Months Ended
	Mar. 31, 2024 USD ($)	Mar. 31, 2024 ILS (₪)	Dec. 31, 2021 USD ($)	Dec. 31, 2020 ILS (₪)
Noncontrolling Interest [Member] | Tanooma Ltd [Member]
Related Party Transaction [Line Items]
Due to related parties current and noncurrent	$ 31,906	₪ 115,725		₪ 115,725
Nexense Technologies LTD [Member]
Related Party Transaction [Line Items]
Related-party transaction rate	5.18%
Nexense Technologies LTD [Member]
Related Party Transaction [Line Items]
Due from related parties			$ 47,623

SCHEDULE OF FAIR VALUE RECURRIN

SCHEDULE OF FAIR VALUE RECURRING BASIS (Details) - USD ($) $ in Thousands	Mar. 31, 2024	Dec. 31, 2023
Platform Operator, Crypto Asset [Line Items]
Financial liability	$ 72	$ 204
Fair Value, Recurring [Member]
Platform Operator, Crypto Asset [Line Items]
Assets
Convertible Loans at fair value	2,160	1,203
Financial liability	72	204
Fair Value, Inputs, Level 1 [Member] | Fair Value, Recurring [Member]
Platform Operator, Crypto Asset [Line Items]
Assets
Convertible Loans at fair value
Fair Value, Inputs, Level 2 [Member] | Fair Value, Recurring [Member]
Platform Operator, Crypto Asset [Line Items]
Assets
Convertible Loans at fair value
Financial liability
Fair Value, Inputs, Level 3 [Member] | Fair Value, Recurring [Member]
Platform Operator, Crypto Asset [Line Items]
Assets
Convertible Loans at fair value	2,160	1,203
Financial liability	$ 72	$ 204

SCHEDULE OF CONVERTIBLE LOANS A

SCHEDULE OF CONVERTIBLE LOANS AT FAIR VALUE (Details) - USD ($) $ in Thousands		3 Months Ended	12 Months Ended
		Mar. 31, 2024	Dec. 31, 2023
Convertible Loans And Warrants
Opening Balance, (including short term loans from related party which is also convertible)		$ 1,203	$ 2,257
Additional convertible loans	[1]		153
Conversion of convertible loan	[2]		(243)
Decrease of notes purchased			(530)
Change in fair value of convertible loans liability		957	(434)
Closing balance		$ 2,160	$ 1,203
[1]During the quarter ended March 31, 2024, and the year ended December 31, 2023, the Company raised a principal amount of nill 152,750 nill 242,538 8,634,616

SCHEDULE OF CONVERTIBLE LOANS_2

SCHEDULE OF CONVERTIBLE LOANS AT FAIR VALUE (Details) (Parenthetical) - USD ($)	3 Months Ended	12 Months Ended
	Mar. 31, 2024	Dec. 31, 2023
Convertible Loans And Warrants
Principal amount		$ 152,750
Converted amount		$ 242,538
Number of shares converted		8,634,616

SCHEDULE OF FAIR VALUES OF WARR

SCHEDULE OF FAIR VALUES OF WARRANTS AND CONVERTIBLE LOAN ASSUMPTION USED (Details)	3 Months Ended	12 Months Ended
	Mar. 31, 2024	Dec. 31, 2023
Class of Warrant or Right [Line Items]
Expected term	2 months 15 days	5 months 15 days
Measurement Input, Price Volatility [Member]
Class of Warrant or Right [Line Items]
Warrants rights outstanding measurement input	87	224
Measurement Input, Expected Dividend Rate [Member]
Class of Warrant or Right [Line Items]
Warrants rights outstanding measurement input
Measurement Input, Risk Free Interest Rate [Member]
Class of Warrant or Right [Line Items]
Warrants rights outstanding measurement input	4.19	5.3
Measurement Input Common Market Value [Member]
Class of Warrant or Right [Line Items]
Warrants rights outstanding measurement input	0.01024	0.015
Old CLA [Member]
Class of Warrant or Right [Line Items]
Expected term (in years)	3 months	6 months
Expected average (Monte Carlo) volatility	83%	213%
Expected dividend yield
Risk-free interest rate	5.46%	5.26%
WACC	27%	27%

SUMMARIZES RELATING TO OUTSTAND

SUMMARIZES RELATING TO OUTSTANDING AND EXERCISABLE WARRANTS (Details) - USD ($) $ / shares in Units, $ in Thousands	Mar. 31, 2024	Dec. 31, 2023
Weighted Average Remaining Contractual life (in years)	2 months 15 days	5 months 15 days
Warrant One [Member]
Warrants Outstanding and Exercisable, Number of Warrants	7,000,000	8,334
Weighted Average Remaining Contractual life (in years)	2 months 15 days	2 years 1 month 28 days
Warrants Outstanding and Exercisable, Weighted Average Exercise Price	$ 0.01024	$ 0.6
Warrants Outstanding and Exercisable, value	$ 71,702	$ 23
Warrant Two [Member]
Warrants Outstanding and Exercisable, Number of Warrants	8,334	32,500
Weighted Average Remaining Contractual life (in years)	1 year 10 months 28 days	2 years 7 months 9 days
Warrants Outstanding and Exercisable, Weighted Average Exercise Price	$ 0.6	$ 0.6
Warrants Outstanding and Exercisable, value	$ 23	$ 116
Warrant Three [Member]
Warrants Outstanding and Exercisable, Number of Warrants	32,500	7,000,000
Weighted Average Remaining Contractual life (in years)	2 years 4 months 9 days	5 months 15 days
Warrants Outstanding and Exercisable, Weighted Average Exercise Price	$ 0.6	$ 0.015
Warrants Outstanding and Exercisable, value	$ 116	$ 203,718

SCHEDULE OF CONVERTIBLE LOANS_3

SCHEDULE OF CONVERTIBLE LOANS AMORTIZED COST (Details) - USD ($) $ in Thousands	3 Months Ended	12 Months Ended
	Mar. 31, 2024	Dec. 31, 2023
Convertible Loans And Warrants
Opening balance	$ 796
Transition from convertible loans measured at fair value to measurement at amortized cost		530
Beneficial conversion feature		(66)
Financial expenses related to transition from fair value measurement to amortized cost		304
Accrued interest through profit or loss	15	28
Closing balance	$ 811	$ 796

SCHEDULE OF NUMBER OF OPTIONS (

SCHEDULE OF NUMBER OF OPTIONS (Details) - Consultants and Employees [Member]	3 Months Ended
	Mar. 31, 2024 $ / shares shares
Number of options, Outstanding balance | shares	62,349,647
Weighted average exercise price, Outstanding balance | $ / shares	$ 0.0007
Number of options, Granted | shares	7,900,000
Weighted average exercise price, Granted | $ / shares	$ 0.00373
Number of options, Exercised | shares	(500,000)	[1]
Weighted average exercise price, Exercised | $ / shares	$ 0.0001	[1]
Number of options, Outstanding balance | shares	69,749,647
Weighted average exercise price, Outstanding balance | $ / shares	$ 0.00107
Number of options, Exercisable balance | shares	25,650,311
Weighted average exercise price, Exercisable balance | $ / shares	$ 0.00136
[1]A board member exercised his options into shares during the quarter

STOCK BASED COMPENSATION (Detai

STOCK BASED COMPENSATION (Details Narrative) - USD ($)	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Share based compensation	$ 172,000	$ 279,000
Chief Financial Officer And Advisor [Member]
Share based compensation	$ 147,000	$ 279,000

SIGNIFICANT EVENTS DURING THE_2

SIGNIFICANT EVENTS DURING THE PERIOD (Details Narrative) - USD ($)		3 Months Ended
	Jan. 01, 2024	Mar. 31, 2024
Additional investment received		$ 456,431
Investment shares issued		7,500,000
Consultant [Member]
Stock option granted	2,300,000
Stock option granted, value	$ 34,350
Option vesting description	The Options are vested on a monthly basis, over a period of 30 months as of the commencement date ending June 30, 2026. The options are exercisable at a per share exercise price of $0.01
Share price	$ 0.01
Consultant One [Member]
Stock option granted	600,000
Stock option granted, value	$ 8,961
Option vesting description	The Options are vested on a monthly basis, over a period of 30 months as of the Commencement Date ending June 30, 2026. The Option are exercisable at a per share exercise price of $0.01
Share price	$ 0.01
Consultant Two [Member]
Stock option granted	5,000,000
Stock option granted, value	$ 74,675
Option vesting description	Upon grant, the Options vest on a monthly basis, over a period of 12 months as of the Commencement Date ending December 31, 2024. The Option are exercisable at a per share exercise price of $0.0001.
Share price	$ 0.0001

SUBSEQUENT EVENTS (Details Narr

SUBSEQUENT EVENTS (Details Narrative) - USD ($)			3 Months Ended
	Jul. 01, 2024	May 14, 2024	Mar. 31, 2024	Mar. 31, 2023	Apr. 01, 2024	Dec. 31, 2023
Subsequent Event [Line Items]
Proceeds from issuance of common stock			$ 381,000
Common stock exercise price			$ 0.0001			$ 0.0001
Issuance related to expense			$ 49,492
Stock issuance total expense			$ 197,966
Subsequent Event [Member]
Subsequent Event [Line Items]
Proceeds from issuance of common stock		$ 1,500,000
Adi Shemer [Member] | Subsequent Event [Member]
Subsequent Event [Line Items]
Number of shares issued	6,000,000
Common stock exercise price	$ 0.0001
Adi Shemer [Member] | Subsequent Event [Member] | Minimum [Member]
Subsequent Event [Line Items]
Number of shares issued	100,000,000
Officer And Director [Member] | Subsequent Event [Member]
Subsequent Event [Line Items]
Options outstanding					6,959,692
Common Stock [Member] | Boris Molchadsky [Member] | Subsequent Event [Member]
Subsequent Event [Line Items]
Share conversion rate		$ 0.07
Outstanding unpaid compensation		$ 70,000,000
Common Stock [Member] | Asaf Porat [Member] | Subsequent Event [Member]
Subsequent Event [Line Items]
Share conversion rate		$ 0.04
Outstanding unpaid compensation		$ 50,000,000
Common Stock [Member] | Adi Shemer [Member] | Subsequent Event [Member]
Subsequent Event [Line Items]
Share conversion rate		$ 0.04